T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy BERLIN, GERMANY, and SOMERSET, N.J. – September 21, 2020 — T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid...

T-knife schließt Serie A Finanzierungsrunde über EUR 66 Millionen zur Entwicklung neuartiger T-Zell-Therapeutika ab T-Zellrezeptoren auf Basis von T-knifes geschützter humanisierter Mausplattform (HuTCR) sollen überlegene Affinität und Spezifität bieten Versant Ventures und RA Capital Management Hauptinvestoren der...

T-knife Completes EUR 66 Million Series A Financing to Develop Next-Generation T-Cell Therapies T-knife’s proprietary humanized mouse platform (HuTCR) T-cell receptors expected to provide superior affinity/specificity properties Series A round led by Versant Ventures and RA Capital Management,...

Aleva Neurotherapeutics Receives CE Mark for its directSTIM™ Deep Brain Stimulation System and Raises USD 8 Million Private Equity Lausanne, Switzerland, December 16, 2019 – Aleva Neurotherapeutics, a leading developer of implants for deep brain stimulation (DBS) in major neurological indications such as Parkinson’s disease and...